Login to Your Account



Strategic Buys Fuel MAb Developer Immune Pharma

By Marie Powers
Staff Writer

Thursday, December 27, 2012
newco_news_resized.jpg

In less than three years, privately held Immune Pharmaceuticals has matured from a start-up launched with a single monoclonal antibody (MAb) licensed from Canada's iCo Therapeutics Inc. into a biotech capable of absorbing the assets of publicly traded EpiCept Corp. in an all-stock deal.

Immune, which has joint headquarters in Herzliya-Pituach, Israel, and New York, is advancing lead compound bertilimumab, a fully human MAb that targets eotaxin, in the initial inflammatory bowel disease (IBD) indications of ulcerative colitis (UC) and Crohn's disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription